Some studies have unveiled that osteopontin and PSA (primary marker in clinical use) plasma levels hold comparable efficacy in predicting treatment outcomes in metastatic PCa post radiotherapy [133]. This evidence concerns the gene SPP1 and posterior cortical atrophy.